Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

This phase II trial compares the effect of the combination of daratumumab-hyaluronidase (daratumumab) and teclistamab to the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and dexamethasone in treating patients with multiple myeloma that has not responded to previous treatment (refractory) or that has come back after a period of improvement (relapsed). Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumuma

Trial Details

NCT ID
NCT06948084
Phase
PHASE2
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Biospecimen Collection
  • Bone Marrow Biopsy
  • Carfilzomib
  • Computed Tomography
  • Daratumumab and Recombinant Human Hyaluronidase
  • Dexamethasone
Locations (sample)
  • Coeur d'Alene, Idaho, United States|47.67768,-116.78047
  • Post Falls, Idaho, United States|47.71796,-116.95159
  • Sandpoint, Idaho, United States|48.27659,-116.55325
  • Bloomington, Illinois, United States|40.4842,-88.99369
  • Canton, Illinois, United States|40.55809,-90.03512

Key Eligibility Criteria

  • Patient must be ≥ 18 years of age
  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 (PS 3 allowed if secondary to pain)
  • Patient must have an identifiable dominant sequence (clonotype) established based on Adaptive Biotechnologies clonoSEQ® assay
  • Patient must have received only one prior line of therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →